Novalis Biotech

Rarity Bioscience specializes in developing molecular amplification technology for the detection of nucleic acid sequences, particularly in biological samples such as liquid biopsies. The company offers an ultrasensitive multiplex assay that can identify small amounts of DNA sequence variants, providing valuable tools for both research and clinical applications. This technology enhances the ability of physicians to detect rare nucleic acid sequences, thereby supporting advancements in diagnostics and personalized medicine.

Alithea Genomics, based in Switzerland, specializes in RNA sequencing and transcriptomics to support biomedical discoveries. The company employs proprietary technology to enhance the efficiency and cost-effectiveness of Ribonucleic acid sequencing, significantly increasing the throughput of analyzed samples. With expertise in bioengineering, molecular biology, and genomics, Alithea Genomics aims to facilitate pharmaceutical companies in their research efforts, ultimately advancing the field of biomedical research.

RheaVita is a pharmaceutical company that specializes in advanced continuous freeze-drying technology for biopharmaceutical products. This innovative technology integrates all steps of the freeze-drying process into a continuous production line, allowing for the constant infeed of products and simultaneous outfeed of dried goods. By improving the manufacturing process, RheaVita's approach addresses the limitations of traditional batch freeze-drying, significantly reducing processing times and minimizing scale-up challenges. The company’s method not only lowers production costs and requires smaller manufacturing facilities with less clean room space, but it also enhances quality assurance through comprehensive inspection and the potential for real-time release. Overall, RheaVita's technology results in improved and consistent product quality, contributing to faster development and reduced time-to-market for pharmaceutical medicines.

Grapheal introduces digital biosensing technology into embedded systems for on-site diagnostics and remote patient monitoring. Current applications are wound care digital assistant for improving the follow-up of difficult to heal wounds.

Enzyre B.V. is a company based in Nijmegen, the Netherlands, founded in 2016. It specializes in developing ambulant diagnostic technology specifically for coagulation testing. The focus of Enzyre is on creating innovative solutions that enhance the accuracy and convenience of diagnostic procedures, particularly in the area of blood coagulation. The company's technology aims to improve patient care by enabling more accessible and efficient testing methods.